Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix in advanced prostate cancer
NCT03085095Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Apr 2017
- Primary completion
- Oct 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 22
01
Overview
A Phase 3 trial of relugolix in prostate cancer (PCa), sponsored by Myovant Sciences. Started Apr 2017; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03085095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085095.